Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sarepta Therapeutics Inc(SRPT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SRPT
09/28/2026: SRPT (1-star) is a SELL. SELL for 4 days. Simulated Profits (-1.40%). Updated daily EoD!
Sarepta Therapeutics is a specialized biotechnology company focused on delivering gene and RNA-based therapies for rare neuromuscular conditions like Duchenne muscular dystrophy. The company has a leading position in the DMD market, driven by its successful exon-skipping franchise and the launch of its gene therapy, Elevidys. Its main growth story centers on expanding these treatments to broader patient groups and advancing its early-stage pipeline. However, investors must navigate risks related to clinical trial outcomes, evolving competition in gene editing, and payer scrutiny over high-cost specialty drugs. Sarepta is best suited for growth-oriented investors and requires monitoring of regulatory approvals, long-term safety data, and commercial adoption trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active commercial scaling phase with a focus on high-growth rare disease therapies. |
| Momentum investor | Strong fit while signal remains positive | Stock performance is heavily influenced by regulatory catalysts and clinical trial updates. |
| Value investor | Weak fit | The company trades primarily on future growth prospects and clinical potential rather than current valuation multiples. |
| Dividend investor | Weak fit | Sarepta is a pre-profit or early-stage commercial company that does not pay dividends. |
| Low-risk investor | Weak fit | The biotechnology sector, specifically in rare diseases, is characterized by high volatility and binary clinical risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on FDA decisions and clinical trial data. |
| Valuation risk | Medium / high | Valuation is often tied to long-term growth expectations for pipeline assets. |
| Competition risk (rare disease therapies) | Medium | New entrants in gene editing and RNA technology threaten the longevity of current product franchises. |
| Business quality | Medium | The business relies heavily on its ability to navigate the complex regulatory and manufacturing landscape. |
| Dividend income | Low / none | Investors should not expect income; capital is prioritized for growth. |
| Execution risk | Medium / high | Successfully manufacturing and distributing one-time gene therapies requires complex operational capabilities. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -56.47% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97B USD | Price to earnings Ratio - | 1Y Target Price 21.86 |
Price to earnings Ratio - | 1Y Target Price 21.86 | ||
Volume (30-day avg) 3.0M shares | Beta 0.26 | 52 Weeks Range 14.68 - 25.32 | Updated Date 09/27/2026 |
52 Weeks Range 14.68 - 25.32 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.57 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| RNA-based Therapies | Exondys 51, Vyondys 53, and Amondys 45 for Duchenne muscular dystrophy. | The company generates steady revenue from recurring patient doses of these personalized treatments. |
| Gene Therapy | Elevidys and early-stage gene therapy clinical assets. | Revenue is generated from high-cost, one-time treatment administrations for rare genetic conditions. |
| Geography | United States and expanding international presence. | The majority of revenue is currently US-based, with international growth being a key long-term focus. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 19.16 | Enterprise Value 2.26B | Price to Sales(TTM) 1 |
Enterprise Value 2.26B | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 1.14 | Enterprise Value to EBITDA 16.91 | Shares Outstanding 105.63M | Shares Floating 100.54M |
Shares Outstanding 105.63M | Shares Floating 100.54M | ||
Percent Insiders 4.88 | Percent Institutions 103.77 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Sarepta Therapeutics Inc
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 1997-06-03 | CEO & Director Dr. Michael E. Severino M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 835 | Website https://www.sarepta.com |
Full time employees 835 | Website https://www.sarepta.com | ||
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.